Fentanyl sublingual - iX Biopharma

Drug Profile

Fentanyl sublingual - iX Biopharma

Alternative Names: WafernylTM

Latest Information Update: 01 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iX Biopharma
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer pain

Most Recent Events

  • 01 Sep 2016 Chemical structure information added
  • 10 Aug 2016 Fentanyl Sublingual is still in phase I development for Cancer pain (iX Biopharma, August 2016)
  • 09 Jun 2016 iX Biopharma has patent protection for WaferiX™ drug delivery technology in South Korea, Japan, Indonesia, Singapore, Australia, New Zealand and Malaysia ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top